result of new information, future events, or otherwise, except as may be required under applicable securities laws. HOLLISTER, Calif., July 12, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the closing of its previously announced private placement for the issuance and sale of an aggregate of 12,385,883 shares of its ...

Core Viewpoint - Alpha Teknova, Inc. has announced a definitive agreement for a private placement of 12,385,883 shares of common stock at a price of $1.24 per share, aiming to raise approximately $15.4 million before expenses [1][7]. Company Overview - Teknova is a leading producer of critical reagents for the life sciences industry, focusing on the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics [1][4]. - The company has been innovating since 1996 and offers customizable solutions for various stages of the workflow, supporting sectors such as cell and gene therapy, molecular diagnostics, and synthetic biology [4]. Financial Details - The private placement is expected to close on or about July 12, 2024, subject to customary closing conditions [7]. - The gross proceeds from the private placement are anticipated to be approximately $15.4 million, which will be used for general corporate purposes [7]. Regulatory Compliance - The securities in the private placement are not registered under the Securities Act and may not be reoffered or resold in the U.S. without an effective registration statement or applicable exemption [3][8]. - Teknova has agreed to file an initial registration statement with the SEC covering the resale of the securities within 45 days of the definitive agreement [8].

The private placement is expected to close on or about July 12, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds to Teknova from the private placement are expected to be approximately $15.4 million, before deducting offering expenses payable by Teknova. Teknova currently intends to use the net proceeds from the private placement for general corporate purposes. HOLLISTER, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (Nasdaq: TKNO), a leading p ...

Company reaffirms 2024 revenue guidance of $35-38 million "I'm excited to share our sustained progress in executing against our strategy," said Stephen Gunstream, President and Chief Executive Officer. "I'm increasingly confident that we will continue to deliver through the end of this year and beyond, in particular as market conditions appear likely to improve, notably with recent FDA approvals of novel gene therapies and with a recovery in biotech and cell and gene therapy funding more broadly." Second qu ...

Company reaffirms 2024 revenue guidance of $35-38 million Business and Financial Updates Clinical Solutions: Teknova has seen an increase in the number of Clinical Solutions customers since fiscal 2023, from 34 to 43. While the Company's overall revenue in fiscal 2024 is expected to be lower within the Clinical Solutions category compared to fiscal 2023, Teknova has successfully grown the number of its customers entering clinical trials and ordering its GMP-grade products, supporting the Company's thesis th ...

A downtrend has been apparent in Alpha Teknova (TKNO) lately with too much selling pressure. The stock has declined 24.6% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversol ...

Investors might want to bet on Alpha Teknova (TKNO) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. The p ...

Alpha Teknova, Inc. (NASDAQ:TKNO) Q1 2024 Earnings Conference Call May 13, 2024 5:00 PM ET Company Participants Jennifer Henry - Senior Vice President of Marketing Stephen Gunstream - President and Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Steven Mah - TD Cowen Matt Larew - William Blair Vidyun Bais - BTIG Operator Good day and thank you for standing by. Welcome to Teknova's First Quarter 2024 Financial Results Conference Call. At ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40538 ALPHA TEKNOVA, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

Corporate and Financial Updates 1 Exhibit 99.1 Teknova Reports First Quarter 2024 Financial Results First quarter 2024 total revenue was $9.3 million, up 2% from prior year Launch of Build-TekTM Custom Configurator Company reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., May 13, 2024 – Alpha Teknova, Inc. ("Teknova" or the "Company") (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular di ...